Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha variable 12-2 encodes the variable domain of the alpha chain in certain T cell receptors, which are essential for the antigen recognition that sparks adaptive immune responses. TCRs are comprised of paired alpha and beta chains (or gamma and delta), and TRAV12-2 contributes to the diversity and specificity of peptide-MHC recognition on antigen-presenting cells. TRAV12-2 use is biased in TCRs recognizing specific antigens (e.g., A2/ELA from Melan-A/MART-1 and A2/Tax from HTLV-1). The germline-encoded CDR1α loop of TRAV12-2 makes major contacts with peptide-MHC complexes, influencing the frequency and prevalence of naïve T cells with this specificity. Variation in TRAV12-2 is relevant to disease-specific immune responses, particularly in cancer and viral infections[1][2][3][4].
Drugs acting on T cell receptors (not specific for TRAV12-2) function via modulation of antigen recognition, T cell activation, or immune checkpoint inhibition. They leverage TCR signaling to enhance or suppress immune responses, but TRAV12-2 specificity is relevant in adoptive T cell therapies targeting specific antigens[4].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha variable 12-2 (TRAV12-2).